| 1 |
35530278 | Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. | 2022 |
3 |
| 2 |
35545724 | Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. | 2022 May 11 |
1 |
| 3 |
35624189 | Selection of Payloads for Antibody-Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study. | 2022 May 27 |
1 |
| 4 |
33882206 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. | 2021 Apr 22 |
1 |
| 5 |
34116144 | Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. | 2021 Sep |
1 |
| 6 |
34176192 | Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. | 2021 Oct |
3 |
| 7 |
34651524 | Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. | 2021 Dec |
2 |
| 8 |
31891442 | Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. | 2020 Mar |
2 |
| 9 |
32082489 | Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. | 2020 Feb 4 |
2 |
| 10 |
32117765 | Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. | 2020 |
4 |
| 11 |
32529410 | Sacituzumab Govitecan: First Approval. | 2020 Jul |
1 |
| 12 |
31208270 | Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. | 2019 Aug/Sep |
2 |
| 13 |
29989029 | The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. | 2018 Jun 22 |
2 |
| 14 |
28291390 | Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. | 2017 Jul 1 |
2 |
| 15 |
28548889 | Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. | 2017 Aug 20 |
2 |
| 16 |
28679770 | Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. | 2017 Oct 1 |
1 |
| 17 |
26541586 | Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. | 2016 Feb |
2 |
| 18 |
26577300 | An ADC for Triple-Negative Breast Cancer. | 2016 Jan |
2 |
| 19 |
27207776 | Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. | 2016 Aug |
2 |
| 20 |
25944802 | First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. | 2015 Sep 1 |
3 |
| 21 |
26101915 | Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). | 2015 Sep 8 |
1 |
| 22 |
21372224 | Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. | 2011 May 15 |
4 |